On this basis, researchers utilized genetic engineering to generate megakaryocyte (MK) progenitor cells expressing PD‐1 or PD‐L1 to obtain PD‐1 or PD‐L1 expressing platelets for the prevention of postoperative tumor recurrence and the reversal of type 1 diabetes mellitus [50, 51]. This evidence concerns the gene PDCD1 and type 1 diabetes mellitus.